lincoff, does this mean that doctors may change how they treat heart patients moving forward? >> i certainly think it will. you know, it's really a standard of care to treat the other risk factors that we know we can modify. we can hypertension, high, high cholesterol, diabetes. so now overweight and obesity is a new pathway. it's emerged, as, you know, what we call a modifiable risk factor. it's not just something we notice, but we can't do anything about it. and it's really now it's on the part of practitioners who care for patients with overweight and obesity if they have heart disease that we should be treating this pathway as well. >> we should mention that this is not a cheap drug. it costs about $1,300 a month and it's not for everybody. but could this mean that people who don't have weight problems may end up taking it like people with heart conditions? >> well, that's very interesting. >> and, you know, the mechanisms are not completely worked out about how it benefits. it's probably multiple effects. some of it certainly is weight loss and the process of weight loss